After the melanomas formed palpable tumours at the injection site, mice were treated orally with the MEK inhibitor trametinib (0.5 mg kg−1 body mass per day) and/or digitoxin (0.5 mg kg−1 body mass per day). The gene discussed is MAP2K7; the disease is neoplasm.